Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acorda resubmits NDA for multiple sclerosis therapy
Acorda received a refuse to file (RTF) letter for the Fampridine-SR new drug application (NDA) on March 30, 2009, which cited the need to correct ‘format issues’ and
Acorda received a refuse to file (RTF) letter for the Fampridine-SR new drug application (NDA) on March 30, 2009, which cited the need to correct ‘format issues’ and
Prior to joining Biocodex Inc, Mr Rohman was part of the senior management team at FlowMedica in Fremont, California, where he was responsible for directing the company’s collaboration
The company has reported net income available to common shareholders of $767 million for the first quarter of 2009 compared to $276 million for the same quarter of
For the first quarter of 2009, total sales were $5.38 billion, a decrease of 8%, compared to $5.82 billion in the same quarter of 2008. Richard Clark, chairman,
Net income attributable to Gilead was $589.11 million or $0.63 diluted earnings per share, for the first quarter of 2009, compared to $488.30 million, or $0.51 diluted earnings
According to the company, Mecan, a European medical device and supplies distributor will be providing logistics and warehouse services for the MedX European distribution center. Following receipt of
The new service provides biopharmaceutical clients with a comprehensive way to measure the genetics of drug metabolism in clinical trial patients – giving drug developers the opportunity to
Amgen reported diluted earnings per share of $0.98 for the first quarter of 2009, a decrease of 3%, compared to $1.01 per share for the first quarter of
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Iressa for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with
Victoza is the brand name for liraglutide, the first once-daily human glucagon-like peptide-1 (GLP-1) analog developed for the treatment of type 2 diabetes, the company said. The positive